Objective: To investigate the clinical effect of modified Qili San and its effects on inflammatory factors and D-dimmer in stoke patients complicated with deep venous thrombosis (DVT) of the lower extremities. Method: One hundred and forty stroke patients complicated with DVT of the lower extremities were randomly divided into control group (n=70) and observation group (n=70) equally according to random number table. On the basis of conventional treatments

the control group was given with urokinase

while the observation group was also given with Qili San on the basis of control group treatment. After treatment for 2 weeks

curative efficacy

level of inflammatory factors [tumor necrasis factor-α(TNF-α)

interleukin-6(IL-6)

IL-8 levels]

D-dimmer and adverse reactions were observed and compared. Result: The observation group had a total effective rate of 92.8%

which was statistically higher than that of 80.0% in the control group (P<0.05). After the treatment

inflammatory factors of TNF-α(1.31±0.06) μg·L-1

IL-6 (113.14±9.08) ng·L-1

IL-8 (0.18±0.03) μg·L-1 in the observation group were respectively significantly lower than those in the control group (all P<0.05). One week and two weeks after the treatment

level of D-dimmer (252.8±21.3) μg·L-1 in the observation group was significantly lower than that in the control group (both P<0.05). During the treatment

there was no case of severe adverse reaction. And the incidence of adverse reactions in the observation group was 11.4%

without significant difference with that of 10.0% in the control groups. Conclusion: Qili San in combination with urokinase is effective for treating stoke patients complicated with DVT of the lower extremities

which can significantly increase curative efficacy

alleviate inflammatory reaction and decrease level of D-dimmer with minor adverse reactions. It is worthy of further study in clinical cases.